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From Ataxia to Diagnosis of Askin Tumor – 
a Case Report
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ABSTRACT
Peripheral primitive neuroectodermal tumors (pPNET) are a group of extremely rare, aggressive, malignant tumors that are most often 
found in the thorax (Askin tumor), abdomen, pelvis, extremities and less frequently in the head and neck. The most important prognostic 
factor is the stage of the tumor. Significant progress both in surgery and in neoadjuvant and adjuvant chemotherapy and radiotherapy, as 
well as the improvement in diagnosis by cytogenetic and immunohistochemical analysis, should improve the survival rate. We report a case 
of a 14-year-old girl, with ataxic gait, cardiopulmonary compensated, without respiratory symptoms, who was referred to our hospital 
for further examination and treatment of newly discovered tumor of the left hemithorax. After a detailed radiological and laboratory 
investigation, next step was an extensive thoraco-neurosurgical surgery. After histopathological, cytological and molecular analysis, 
a diagnosis of Askin tumor was made.
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INTRODUCTION
Primitive neuroectodermal tumors are groups of highly 
malignant tumors composed of small round cells of neu-
roectodermal origin. They show a great variety in clinical 
manifestations and a great cytological similarity to other 
small cell tumors, which through the past classification 
of this tumor group caused a series of controversies. Al-
though Askin’s tumor was first described in 1979 (1), only 
Batsakis et al. (2) the family of primitive neuroectodermal 
tumors divided into three groups; I. primitive neuroecto-
dermal central nervous system tumor, II. neuroblastoma, 
III. peripheral primitive neuroectodermal tumor (pPNET – 
tumors that originate from tissues outside the central and 
autonomic nervous system). Peripheral primitive neuroec-
todermal tumors are also classified as part of Ewing’s tumor 
family because they represent different manifestations of 
the same tumor and have similar genetic changes. Ew-
ing’s sarcoma is more common in bones, while peripheral 
primitive neuroectodermal tumors are more common in 
soft tissues. Immunohistochemical and cytogenetic studies 
indicate that these tumors have a common origin (known 
to share the same reciprocal translocation, most commonly 
between chromosomes 11 and 22), and therefore peripher-
al primitive neuroectodermal tumors are divided into the 
following groups; I. Ewing’s sarcoma, II. malignant periph-
eral primitive neuroectodermal tumors (peripheral neu-
roepithelioma of bone and soft tissues), III. Askin’s tumor 
(peripheral neuroepithelioma of the thoracopulmonary 
region), IV. other rare tumors (neuroectodermal tumor, ec-
tomesenchymoma, peripheral medullary epithelioma) (3). 
Peripheral primitive neuroectodermal tumors have very 
often aggressive clinical behavior compared to other tu-
mors that originate from small round cells of neuroecto-
dermal origin. They are exceptionally rare with an annual 
incidence (in the age group from the age of 20 years) of 
2.9 patients per million inhabitants. In recent major stud-
ies, peripheral primitive neuroectodermal tumors mostly 
occur in the second decade of life with slightly higher fre-
quency in male populations. There are 4–17% of all soft-tis-
sue tumors in the children’s population and dominate in 
children of white race and Latino Americans origin (4).
CASE REPORT
A 14-year-old girl, born of proper pregnancy and childbirth, 
normal psychomotor development, regular personal and family 
anamnesis, came to the local hospital due to fatigue in her legs 
which appeared ten days ago. During the examination, the girl 
was afebrile, oriented in time and space, regular speech, cardi-
opulmonally compensated, without respiratory symptoms, with 
the asymmetry of the lips and ataxic gait. The thorax was asym-
metrical with the protuberance of left hemithorax (Figure 1). 
The auscultatory finding on the heart was tidy, on the both 
lungs hearing breathing with the left apical rear silent breathing 
sound. The walk on the heels and fingers did not work, and she 
stood up adhering to table. She was unstable in Romberg. In the 
antigravitational position she had a trembling hand. The tetive 
muscular reflexes of the lower extremities were extended reflex 
zones. Skin reflections at all levels were not challenged. Head 
CT, abdominal ultrasound and lumbosacral spine x-ray were 
initiated. Head CT and abdominal ultrasound were tidy while 
lumbosacral spine x-ray noticed soft tissue shadow of the left 
hemithorax, followed by initiation of chest x-ray by verifying 
the large shadow of the left hemithorax that suppressed the me-
diastinal structure contralaterally and compressed the pulmo-
nary parenchymal caudally (Figure 2). The right lung was free 
of inflammatory and delayed changes. There was no pleural 
effusion. In the area of the 5th rib on the left was a visible lytic 
lesion susceptible to osteolysis. With the diagnosis of neoplasm 
of uncertain or unknown etiology, the girl was transferred to 
the Children’s Hospital Zagreb for further treatment. It is ini-
tiated ECG, echocardiogram, thoracic ultrasound and CT, MR 
of neuroaxis and complete laboratory findings. The echocardi-
ogram showed a fully accurate finding while the ECG recorded 
sinusoidal frequency 84/min, vertical electric axis (+92 °), time 
intervals with repolarization disturbance. The thoracic CT was 
verified by a large, sharply restricted tumor formation of the left 
chest extending from the apical to the base at a length of 22 cm 
(Figure 3a), while spreading the volume of the thorax leading to 
the thoracic wall protrusion (Figure 3b). The tumor suppressed 
the mediastinal structures contralaterally without infiltrating 
them. The left bronchus was shown in the initial part, while it 
was later covered by tumor formation. Tumor formation was 
mixed characteristics of the inhomogeneous structure, partially 
filled with denser fluid content absorption coefficient between 
20–30 HU, while in the back was predominantly intercalated 
with calcifications and fibrous elements. The back part of the 
fifth rib in the length of 50 mm was destroyed as well as the 
associated costovertebral joint. MR of neuroaxis at ThIV, ThV 
and ThVI levels showed intraspinal propagation of tumor 
of extradural position (Figure 4). Laboratory findings were 
within normal limits except for the following; sedimentation 
75 (↗), lactate dehydrogenase 258 (↗), ferritin 156 (↗), NSE 
20.2 (↗). On the third day, ultrasound was performed by 
percutaneous puncture biopsy through the third intercostal 
space in the posterior axillary line. The tissue cylinder referred 
to pathohistological and cytological analysis that did not find 
tumor cells. On the tenth day, a combined thoraco-neurosurgical 
surgery was initiated. The surgical procedure involved a left 
thoracotomy, full extirpation of a huge tumor spreading into 
the spinal canal, decompression laminectomy (ThIV–ThVI) 
and the 5th rib resection. The final diagnosis was obtained by 
a pathohistological, cytological and molecular analysis. The 
tumor was encapsulated, partly cystic, in a solid part with the 
necrosis. It was a tumor of small blue round cells constructed of 
diffuse proliferation of uniform cells of blastoid nuclei, gentle 
chromatin of scarce cytoplasm, with numerous apoptotic bodies 
and with 10 mitoses at 10 VF. Immunohistochemical, described 
tumor cells were vimentin, CD 99, and a smaller portion of 
NSE positive whereas only CKAE1/AE3, EMA and S100 were 
positive. The Ki67 proliferation marker was positive in 20% 
of tumor cells. RT-PCR determined translocation t (11; 22) 
(q24; q12) EWSR1/FLI1. Multiple times, chest x-ray indicated 
incomplete reexpand left pulmonary parenchyma which was 
also expected due to long compression (Figure 5). On the 
eighth postoperative day, the thoracic drain was replaced by 
a pleurostomia catheter connected to the Heimlich valve 
and a chemotherapy treatment with the VIDE (vincristine, 
ifosfamide, doxorubicin, etoposide) initiated according to 
EURO-E.W.I.N.G. 99 protocol.
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DISCUSSION
By reviewing literature, most peripheral primitive neuro-
ectodermal tumors are affected by thorax (Askin’s tumor), 
pelvis, abdomen and extremities (5, 6, 7). Thoracic involve-
ment is described in more than sixty cases. Interesting-
ly, in the series of Jones and McGill tumor localization as 
many as 11 out of 26 patients in the area of the head and 
neck (8). Clinical symptoms depend on the localization and 
on the stage of the tumor. It is interesting to note that the 
patient from our presentation had no symptoms of pain in 
the chest wall, dyspnea, cough, and weight loss as we can 
notice in other reports (9, 10). Ataxia, as the leading symp-
tom, has not been recorded in any case so far. Literature as 
Fig. 1 The patient with discrete prominence left 
hemithorax.
Fig. 2 Chest x-ray – a large soft tissue shadow of left hemithorax 
which suppresses mediastinal structures contralaterally and 
compresses the lung parenchyma caudally with subsequent 
subsegmental plate atelectasis. Osteolytic lesions of the 5th rib 
(marked with an arrow).
Fig. 3 Thorax CT (a – sharply limited tumor formation of the left chest that extends from the apex to the base in the length of 22 cm;  
b – transverse cross-section of the thorax showing the forward bulging of the thoracic wall).
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the leading cause of ataxia states the following conditions; 
central postinfectious and inflammatory causes, acute 
postinfectious cerebellar ataxia, postinfectious cerebel-
litis, ADEM, the clinically isolated syndrome, MS, spinal 
and peripheral postinfectious and inflammatory causes, 
Guillaine-Barré syndrome, Miller Fisher syndrome, Bick-
erstaff brainstem encephalitis, transverse myelitis, toxic 
ingestion (benzodiazepines, antiepileptics: carbamaze-
pine and phenytoin, cough syrup: dextromethorphan, eth-
anol, marijuana), childhood stroke, intracranial bleeding, 
vertebral artery dissection, cerebellar venous infarction, 
meningitis, rhombencephalitis, labyrinthitis and celiac 
disease (11). In several large series of metastases, 21–30% 
of patients (lungs, bones, bone marrow) have been report-
ed. The two-year survival rate is 28–38%, and five-year 
survival rate is only 14–17% (6, 12).
 As far as tumor diagnostics are concerned, data ob-
tained by light microscopy, cytogenetic analysis and im-
munohistochemical methods are of crucial importance 
in the definitive diagnosis of Askin’s  tumor. Based on 
histological studies alone, it is impossible to distinguish 
Askin’s tumor from e.g. rhabdomyosarcoma, neuroblasto-
ma or mesenchymal chondrosarcoma, where in all cases 
we find small, round, dark-colored cells. Electron micros-
copy in peripheral primitive neuroectodermal tumors 
reveals neurosecretory granules with microtubules and 
microfilaments. The final diagnosis by which peripher-
al primitive neuroectodermal tumors are distinguished 
from other small, round cell tumors and represented by 
most pathologists and cytologists is based on the immu-
nohistochemical analysis of MIC2 (CD99) gene expression 
that produces an antigen (13). Recently, the immuno-his-
tochemical analysis of NKX2-2 gene product has become 
increasingly important (8). There are other nonspecific 
markers that are also used in the diagnosis of this tumor 
group; S-100, vimentin, neuron specific enolase, CD75 and 
synaptophysin (14).
 Radiology, primarily in the form of computerized to-
mography and magnetic resonance, definitely helps us 
to determine the limits of the tumor and the presence of 
metastasis. At CT, peripheral primitive neuroectodermal 
tumors primarily appear as heterogeneous masses, often 
infiltrating surrounding tissues. According to Ba et al. 
these tumors were hypodense, and osteolytic focal points 
were a sign that the tumor originated from the bone (15). 
Analogously to our radiological finding Xiao et al. as the 
main CT characteristics of these tumors described an ir-
regular form (83.3%), heterogeneity (66.7%) and hypoden-
sity (94.4%) (16).
 As far as treatment is concerned, current guidelines 
are in favor of complete surgical resection (17). It is nec-
essary, as far as possible, to completely remove the tumor, 
although this is not always possible with regard to the in-
filtration of vital structures. Chemotherapy and radiother-
apy (adjuvant and non-adjuvant) are also key in treating 
this tumor. A review of literature is based on a series of 
protocols ranging from only two to six chemotherapeu-
tics (18). Combinations used in the largest number of cas-
es are doxorubicin, actinomycin D, cyclophosphamide, 
ifosfamide, vincristine, etoposide, busulfan, melphalan 
and carboplatin (VACA – vincristine, doxorubicin, cyclo-
phosphamide, actinomycin, VAIA – vincristine, doxoru-
bicin, ifosfamide, actinomycin, EVAIA – VAIA + etoposide; 
VIDE – vincristine, ifosfamide, doxorubicin, etoposide) 
(19). Carvajal and Meyers, with a comprehensive review 
of chemotherapy protocols and outcomes, recommended 
Fig. 5 X-ray of the lungs after the surgery – incomplete reexpansion 
of the lung parenchyma with resection of the 5th rib.
Fig. 4 MR of neuroaxis (sagittal section) – intraspinal propagation 
of the tumor process at the ThIV, ThV and ThVI level (indicated by 
the arrow).
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the following regimen; vincristine, doxorubicin and cyclo-
phosphamide with ifosfamide and etoposide (20). More 
recently, the use of adjuvant radiotherapy with doses 
greater than 60 Gy has been abolished since studies have 
shown that doses greater than 60 Gy are causing second-
ary malignancies. Kuttesch et al. reported that 20% of pa-
tients who received a dose greater than 60 Gy developed 
secondary malignant neoplasm (21).
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